Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.
OBJECTIVE
To assess the health care utilization and cost of illness for osteoarthritis (OA) patients taking pain medications. Specifically, the goals were to estimate the direct health care and indirect costs of OA.


METHODS
A claims database of privately insured patients was used to identify OA patients. Prescription drug pain treatments included tramadol, cyclooxygenase-II inhibitors, and nonsteroidal anti-inflammatory drugs. Mean annual per patient costs were calculated from an employer's perspective.


RESULTS
OA patients were prescribed multiple drugs simultaneously and/or sequentially to manage pain. OA patients had a number of prevalent comorbid conditions. Average annual direct medical, drug, and indirect work loss costs were $8601, $2941, and $4603, respectively.


CONCLUSIONS
There was a substantial payer burden associated with OA resulting from the drug, medical, and disability costs and OA-related comorbidities and high concomitant medication utilization.
White
Alan G
AG
Analysis Group, Inc., Boston, MA 02199, USA. AWhite@analysisgroup.com
Birnbaum
Howard G
HG
Janagap
Carmela
C
Buteau
Sharon
S
Schein
Jeff
J
D000701:Analgesics, Opioid / Q000191:economics*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics*; D017281:Cost of Illness; D003365:Costs and Cost Analysis; D051546:Cyclooxygenase 2 / Q000191:economics*; D005260:Female; D006801:Humans; D007345:Insurance Claim Review; D019458:Insurance Coverage; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy / Q000191:economics / Q000503:physiopathology*; D010146:Pain / Q000188:drug therapy*; D014147:Tramadol / Q000191:economics*; D014481:United States
D000701:Analgesics, Opioid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D014147:Tramadol; D051546:Cyclooxygenase 2